Home / Join Newsletter / Careers / Contact Us
Soligenix

  • About Us
    • Company Overview
    • Leadership
  • Pipeline
    • Overview
    • Clinical Trials
    • BioTherapeutics
      • SGX301 – for the treatment of Cutaneous T-Cell Lymphoma
      • SGX203 – Oral BDP for Treating Pediatric Crohn’s Disease
      • SGX942 Oral Mucositis
      • SGX201 – Oral BDP for Preventing Acute Radiation Enteritis
    • Vaccines / BioDefense
      • ThermoVax® – Thermostability Technology
      • RiVax® Ricin Toxin Vaccine
      • OrbeShield® for Gastrointestinal Acute Radiation Syndrome (GI ARS)
      • SGX943 – Therapeutic Emerging Infectious Disease
    • Reference Literature
  • Investors
    • Fact Sheet (pdf)
    • SGX94 (Dusquetide) Executive Summary (pdf)
    • Analyst Coverage
    • SEC Filings
  • Partnering
    • In-Licensing
    • Out-Licensing
  • News & Events
    • Current Releases
    • Relevant Publications

News & Events

You are here: News & Events
0
0
0
0
0
  • Wednesday, March 11th, 2015
    Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine
  • Thursday, March 5th, 2015
    Soligenix to Present at the 27th Annual ROTH Conference
  • Tuesday, March 3rd, 2015
    Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
  • Friday, February 13th, 2015
    Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
  • Wednesday, February 11th, 2015
    Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
  • Saturday, February 7th, 2015
    FDA Grants Soligenix “Fast Track” Designation for SGX301 for the First-Line Treatment of Cutaneous T-Cell Lymphoma
  • Thursday, February 5th, 2015
    Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City
  • Monday, February 2nd, 2015
    Soligenix Announces Presentation and Poster at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
  • Thursday, January 29th, 2015
    Soligenix Announces Publication Successfully Demonstrating Enhanced Immunogenicity of its Heat-Stable Anthrax Vaccine
  • Monday, January 5th, 2015
    Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome
  • Monday, December 29th, 2014
    Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data
  • Wednesday, December 24th, 2014
    Soligenix Announces Closing of Public Offering of Units
  • Friday, December 19th, 2014
    Soligenix Announces Pricing of Public Offering of Units
  • Thursday, December 11th, 2014
    Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program
  • Wednesday, December 10th, 2014
    Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer
  • Monday, November 17th, 2014
    Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board
  • Monday, November 10th, 2014
    Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma
  • Tuesday, September 23rd, 2014
    Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
  • Friday, September 19th, 2014
    Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine
  • Wednesday, September 17th, 2014
    Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma
  • <<
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • >>

  • Current Releases
  • Relevant Publications
Legal Notice / Sitemap /
Website design by PING
Copyright © 2019 Soligenix Theme by: ThemeGrill Powered by: WordPress